Kymab has announced the appointment of Simon Sturge as the company’s new CEO, having moved from Merck KGaG for the role.
Mr. Sturge brings to Kymab over 30 years of international leadership experience in both the biotechnology and pharmaceutical industry, and joins the company from Merck KGaA, where he was executive vice president global strategy, business development & global operations. Previously, he was chief operating officer of Merck Healthcare, responsible for company’s global commercial and manufacturing operations. Over the past five years, he has been responsible for the continued growth in global sales at Merck KGaA, as well as the commercial launches of Bavencio (anti-PD-L1 avelumab) in solid tumours and Mavenclad (cladribine) for relapsing multiple sclerosis.
“We are delighted that such an experienced leader as Simon will lead Kymab to its next stage of growth,” said Martin Nicklasson, non-executive chair. “Led by Simon, Kymab will continue to progress its innovative portfolio of products through the clinic and to market, driving our strategy to transform patients’ lives.
“This appointment is part of Kymab’s strategy to position itself for long-term success, building on the incredibly strong R&D foundation of the Company. We’d also like to thank David for many years of leadership at Kymab as CEO and previously as Chair – his leadership has been instrumental to the Company’s evolution.”
His appointment will be effective from May 1, 2019.
